Report on extraordinary general meeting held in NeuroSearch A/S

Announcement

Report on extraordinary general meeting held in NeuroSearch A/S

Pursuant to announcement, the extraordinary general meeting of NeuroSearch A/S
(NEUR.CO) was held today Monday 14 May 2007. 

The suggested amendments to the Articles of Association were adopted by the
general meeting: article 5 following which the board of directors is authorized
to increase the company's capital in one or more issues of a total of nominally
DKK 60,000,000 (3.000.000 shares of DKK 20 each) is prolonged until 30 December
2011, article 5a regarding the authorization of the board of directors to issue
warrants by one or more issues for up to a total of nominally DKK 7,000,000
shares to some or all of the Company's or the Company's subsidiaries'
employees, board members and management on terms laid down by the board of
directors for the period ending on 31 December 2008 and article 10 regarding an
updated of the form and notice of general meetings on the basis of the current
Danish Companies Act. 


Asger Aamund
Chairman of the Board


Contact person: Hanne Leth Hillman, Vice President, Director of Investor
Relations & Corporate Communications, telephone: +45 4460 8212 or +45 4017 5103 


NeuroSearch is a Scandinavian biopharmaceutical company listed on the
Copenhagen Stock Exchange (NEUR). Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channel and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises nine clinical development programmes: ACR16 for the
treatment of Huntington's disease (under preparation for Phase III),
tesofensine for the treatment of obesity/type 2 diabetes (Phase II), NS2359 for
the treatment of depression (Phase II) and ADHD (Phase II) in partnership with
GSK, NS1209 for the treatment of epilepsy and pain (Phase II), ABT-894 for the
treatment of ADHD (Phase II) and neuropathic pain (Phase I) in partnership with
Abbott, ACR16 for the treatment of schizophrenia (Phase I) in partnership with
Astellas and ACR325 for the treatment of psychoses such as bipolar disorder
(Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug
candidates and has equity interests in several biotech companies.